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Abstract Many laboratories use enzyme immunoassays
(EIAs) for the diagnosis of Clostridium difficile infection
(CDI). More recently, polymerase chain reaction (PCR)-
based diagnosis has been described as a sensitive test.
Real-time PCR for the detection of C. difficile toxin A
and B genes was evaluated. A prospective evaluation
was performed on stool samples from 150 hospitalized
adult patients and 141 healthy volunteers. PCR was
compared to toxigenic culture (TC), direct cytotoxicity
test (CTT), ImmunoCard® Toxin A and B (Meridian
Bioscience), and enzyme-linked immunosorbent assay
(ELISA) (Vidas). The results were correlated with clinical
data using a standardized questionnaire. The diagnostic
yield of the PCR was further evaluated after implementa-
tion. Using toxigenic culture as the gold standard, the
sensitivity and specificity of PCR were 100 and 99.2%,
respectively. Patients were categorized as follows: TC/PCR-
positive (n017) and negative TC (n0133). The differ-
ences in these groups were more frequent use of anti-
biotics and leukocytosis (p<0.05). The diagnostic yield
of PCR was evaluated during a period of 6 months and
showed an increase of positive patients by 50%. PCR for
the detection of toxigenic C. difficile has a high sensitivity
and can rule out CDI, but cannot differentiate CDI from
asymptomatic carriage. Clinicians should be aware of this
in order to prevent inappropriate treatment and delay of
other diagnostics.
Introduction
The laboratory diagnosis of Clostridium difficile infection
(CDI) is based on the demonstration of toxin A/B directly in
stool samples or in culture after isolation of the pathogen.
The direct cytotoxicity test (CTT) has been the gold stan-
dard in laboratory diagnosis; more recently, toxigenic cul-
ture (TC) has been used for this purpose [1]. Both methods
are not suitable for routine diagnosis since results are
delayed (at least to more than 24 h), they are labor-
intensive, and fresh cell cultures are needed. To overcome
these problems, numerous enzyme immunoassays (EIAs)
have been developed which are now used widely in clinical
laboratories [2]. However, the described performance of
EIAs varies widely, with sensitivity and specificity rang-
ing from 23 to 99% and 70 to 100%, respectively [3–9].
More recently, polymerase chain reaction (PCR) has been
studied in the diagnosis of CDI [8, 10–13]. A number of
studies demonstrate that PCR is a sensitive diagnostic
test. The reported specificities range between 94 and
99.2%, which may result from the lower sensitivity of
the gold standard, a common problem in the evaluation
of the highly sensitive PCR-based methods. Furthermore,
asymptomatic carriage of toxigenic C. difficile has been
described in 0.5–13% of adults and may be of concern to
the use of PCR.
In the current prospective study, PCRwas compared to TC,
CTT, and two EIAs for the routine diagnosis of CDI. In
contrast to published PCR studies, our test results were corre-
lated to clinical presentation and follow-up. To estimate the
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potential problem of asymptomatic carriage, PCR was per-
formed in healthy volunteers.
Materials and methods
Setting and specimens
The study was performed in a tertiary teaching hospital with
approximately 30,000 patient admissions annually. Initial
PCR evaluation was performed on 45 culture-positive stool
samples. Thereafter, consecutive stool specimens that were
submitted to the routine clinical microbiology laboratory for
C. difficile toxin detection were collected prospectively from
150 hospitalized adult patients. Only one specimen per
patient was included. No outbreaks of diarrheal pathogens
were recorded by the hospital infection control unit of our
hospital in the study period.
Upon receipt at the laboratory, the routinely used
diagnostic ImmunoCard® Toxin A and B test (ICTAB)
was performed and four aliquots of the stool specimen
were stored at −80°C for subsequent testing in batch by
TC, PCR, CTT, and enzyme-linked immunosorbent assay
(ELISA).
To correlate test results with clinical presentation, clinical
data on signs and symptoms were collected. To assess the
occurrence of asymptomatic carriage, healthy adult volun-
teers were recruited among medical students and hospital
employees. Volunteers were informed on the purpose of the
study and that the results would not be reported. Exclusion
criteria for volunteers were the use of antibiotics or com-
plaints of diarrhea. All specimens were thawed only once
before testing in batch. Specimens from all volunteers were
tested by TC and PCR, and positive specimens were further
tested using ICTAB, ELISA, and CTT.
The study was approved by the hospital ethics committee.
Routinely used enzyme immunoassay (ICTAB)
The routinely used diagnostic ICTAB test ImmunoCard®
(Meridian Bioscience, Cincinnati, OH, USA) was performed
following the manufacturer’s instructions. The results were
interpreted independently by two technicians.
Toxigenic Culture (TC)
C. difficile selective agar with cefoxitin, amphotericin B and
cycloserine (CLO, bioMérieux), and Columbia blood agar
with colistin and nalidixic acid (CAP, Oxoid, Cambridge,
UK) were inoculated with 10 μl of the stool specimen. The
media were incubated for 5 days under anaerobic conditions
at 37°C. Colonies with growth characteristics of C. difficile
were investigated by sequence analysis of the 16S rRNA for
identification [14]. C. difficile isolates were subcultured in
brain heart infusion (BHI, CM0225, Oxoid) for the detec-
tion of toxin production using the cytotoxicity test and PCR
detecting genes encoding for toxin A and B.
Ribotyping was performed on all isolates by the National
Reference Laboratory for Clostridium difficile.
Direct cytotoxicity test (CTT)
The CTT was used to determine the presence of toxin in
stool samples (direct CTT) and toxin production in C. difficile
isolates (TC).
The supernatant of 1 mg stool suspended in 1 ml phos-
phate buffered saline (PBS) was filtered through a 0.45-μM
filter (Millipore®, Billerica, MA, USA). Quantities of 20 μl
of filtrate and 20 μl of filtrate with 20 μl of anti-C. sordellii
antitoxin (SAT, Uniprom, T5000, Krimpen aan de IJssel, the
Netherlands) were incubated on Vero cells for 48 h at 37°C.
Appropriate controls were included with each micro-titer
plate used, i.e., 20 μl of toxin (C. difficile Bess strain),
20 μl of SAT, and 20 μl toxin with 20 μl SAT. The specimen
was positive if 50% of the cells showed a characteristic
cytopathic effect (cell rounding) which was neutralized
by SAT.
The cytotoxicity of the isolates was tested as described
above using a 25-μl aliquot of BHI after filtering through a
0.45-μM filter.
PCR
DNA extraction: 200 μl supernatant of a 10% fecal sus-
pension in PBS was used for DNA isolation on MagNA
Pure LC using the MagNA Pure LC Total Nucleic Acid
Isolation Kit (Roche Diagnostics, Almere, the Nether-
lands). For PCR on cultured bacteria, a single colony
was boiled for 10 min in 50 μl of glycerol broths. Quan-
tities of 5 μl of the prepared DNA were used for the PCR
reactions.
Real-time PCR assay: a triplex real-time PCR assay was
developed to simultaneously detect the C. difficile tcdA and
tcdB toxin genes and the gB polymerase gene of phocine
herpes virus (PhHV-1), which served as the internal control
[15]. A positive PCR result did not distinguish between the
presence of the toxin A and/or B gene; tcdA primers and
probes were adapted from Bélanger et al.[16], i.e., the anti-
sense molecular beacon was replaced by a sense TaqMan
probe (5′-CTACTAgAggAAgAgATTCAAAATCCTCA-
3′); tcdB and PhHV primers and probes were as described
[12, 15]. PCR mixes consisted of 25 μl of 2×LC480 Probes
Master (Roche Diagnostics, Almere, the Netherlands),
0.5 μM of each primer and 0.1 μM of each probe, and
5 μl of extracted DNA. Real-time PCR was performed on
a Roche LC480.
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DNA sequencing for confirmation of the identification of
C. difficile: 16S rRNA gene sequences were determined
using primers described by Weisburg et al. [14]. All DNA
sequences were determined using a BigDye Terminator
version v3.1 cycle sequencing kit (ABI) and an ABI 3100
DNA sequencer.
ELISA
The VIDASCDAB test (biomérieux,Marcy-l’Etoile, France),
an ELISA for the detection of toxin A and B, was performed
according to the manufacturer’s instructions. All stool samples
were tested in batch by one technician.
Clinical evaluation
Demographic data and laboratory results were collected
from the electronic patient files. Patients’ medical history
and current signs and symptoms were collected by inter-
viewing the attending physician and reviewing the medical
charts using a standardized questionnaire. Data collected
included reason for and duration of admission, character-
istics of the current episode of diarrhea (consistency,
frequency, duration, and abdominal pain), C-reactive pro-
tein (CRP) and white blood cell count (WBC), use of
antibiotics in the previous 3 months, and the presence of
other risk factors for C. difficile infection (prior hospitaliza-
tion, use of immunosuppressive medication, proton pump
inhibitors, gastric tube feeding, chemotherapy, abdominal
surgery).
The clinical course was evaluated retrospectively in
patients who were negative by ICTAB but were positive
by PCR in order to investigate the clinical significance of
these positive results.
Diagnostic yield after implementation of the PCR
The results of C. difficile detection in routine clinical
specimens were extracted from the laboratory informa-
tion system for the first 6 months after implementation
of the PCR and compared to the results obtained in the
6 months prior to implementation of the PCR when
laboratory diagnosis was based toxin detection using
ICTAB. All PCR-positive specimens were cultured as
described above.
Statistical analysis
The Chi-squared test and Fisher’s exact test were used to
analyze the significance of clinical parameters.
Results
All of the 45 culture-positive stool samples from the initial
evaluation were positive on PCR testing.
A total of 150 patients were included during a 2-month
period, of which 49.7% were male and the median age was
61 years (range 19–95). Most patients were admitted to the
medical wards (56%), followed by the surgical (20.7%) and
hematology/oncology wards (20.7%) and the intensive care
units (2.6%).
Using the TC as the gold standard, the sensitivity, spec-
ificity, positive predictive value (PPV), and negative predic-
tive value (NPV) of the PCR, ICTAB, ELISA, and CTT are
shown in Table 1.
TC was positive in 17 patients (11%). PCR was positive
in 18 patients, including all 17 TC-positive patients, as well
as one patient with negative results for all other tests and
repeated negative stool cultures. CTT was positive in 12
patients, all of whom had a positive TC. The routinely used
ICTAB was positive in nine patients; eight of these patients
had a positive TC. The ELISA was positive in 16 patients,
but only ten of these had a positive TC. Equivocal ELISA
results were found in five patients, and three of these had a
positive TC. Respectively, 5, 9, and 4 patients with a posi-
tive TC were negative using CTT, ICTAB, and ELISA. An
overview of all the test results is presented in Table 2.
The isolates belonged to the following ribotypes: ICTAB-
positive: 001, 011, 014, 018, 053, 056, and 078; ICTAB-
negative: 001, 002, 014, 046, 079, 165, and two unknown.
Two ICTAB-negative but TC- and PCR-positive specimens
contained the ribotypes known to cause false-negative
ICTAB results.
According to the laboratory findings, the patients were
categorized in patients with a positive TC (n017), of which
five had a negative CTT, and a negative TC (n0133).
Patient characteristics and clinical data were compared in
these patient categories (Table 3). More prior antibiotic use
and a higher occurrence of elevated WBC was present in
patients with a positive TC (p<0.05). Within the group of
Table 1 Sensitivity, specificity,
positive predictive value (PPV),
and negative predictive value
(NPV) using toxigenic culture
(TC) as the gold standard
Sensitivity Specificity PPV NPV
Polymerase chain reaction (PCR) 100% 99.2% 94.4% 100%
Direct cytotoxicity test (CTT) 70% 100% 100% 96.3%
ImmunoCard® Toxin A and B (ICTAB) 47% 99.2% 88.9% 93.6%
Enzyme-linked immunosorbent assay (ELISA) 58.8% 89.4% 62.5% 96.7%
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patients with positive TC, no differences were found between
patients with positive (n012) and negative CTT (n05); how-
ever, the number of patients was low. There was only one
patient with a positive PCR only.
The median cycling time (CT) value of PCR was 26.44
(range 21.58–34.69) for CTT-positive stool samples, 38.15
(range 25.51–38.36) for CTT-negative stool samples, and
36.32 for the TC/CTT-negative stool sample.
The clinical course was investigated retrospectively in
ten patients who were not diagnosed by our routinely used
ICTAB (Table 4), i.e., nine patients with positive TC and
PCR, and one patient with a positive PCR only. Five of
these patients also had a positive CTT. One of these
patients (patient 5, Table 4) was diagnosed with pseudo-
membranous colitis (PMC) by endoscopic evaluation, and
one patient (patient 2) was clinically diagnosed with CDI
despite the negative laboratory result. Both patients recov-
ered with metronidazole therapy. One patient (patient 1)
recovered after the treatment of graft-versus-host disease
(GVHD), which was diagnosed by the histological exam-
ination of colon biopsies, and in the two other patients
(patients 3 and 4), symptoms resolved within 2 days
without treatment, despite the continuation of antibiotic
therapy.
Four patients had a positive TC and PCR but negative CTT.
One patient (patient 6) was diagnosed with GVHD by the
histology of colon biopsies and died because of extensive
disease. One patient (patient 7) had severe diarrhea and recov-
ered from recurrent episodes of diarrhea in a timescale of
several months without intervention. One patient (patient 8)
recovered within two days without intervention. One patient
(patient 9) was admitted with diarrhea after antibiotic treat-
ment and recovered with calcium supplements for hemodial-
ysis treatment. The patient with a positive PCR (patient 10)
only developed recurrent episodes of diarrhea during multiple
treatment courses with antibiotics and recovered each time
after the cessation of treatment.
To estimate the potential problem of asymptomatic car-
riage, PCR was performed in healthy volunteers. During a
2-month period, specimens were submitted by 141 unique
volunteers. Of these, 30.5% were male, and the median age
was 25 years (range 18–76). Most volunteers were students
(49%), followed by non-medical hospital employees (27%),
laboratory technicians (17%), and physicians (7%). TC,
PCR, and CTT were positive in 1 (0.7%) volunteer, and
ICTAB was negative.
In our laboratory, unformed stool specimens are tested for
C. difficile toxin at the doctor’s request and if the patient has
been admitted for 72 h or more. After implementation of the
PCR in the routine laboratory, the percentage of patients
Table 2 Test results for the different tests in 150 patients
Number of patients TC PCR CTT ICTAB ELISA
7 + + + + +
2 + + + − +
3 + + + − Eq
1 + + − − +
3 + + − − −
1 + + − + −
1 − + − − −
1 − − − + −
6 − − − − +
2 − − − − Eq
123a − − − − −
a Four patients had a non-toxigenic strain
Eq: equivocal on repeated testing
Table 3 Patient characteristics and clinical data of patients with pos-
itive and negative TC
TC-positive (n017) TC-negative (n0133)a
Fever >38.5°C 5/16 (31%) 50/127 (39%)
Diarrhea
>48 h 9/17 (53%) 64/133 (49%)
>24 h 2/17 (11%) 23/133 (17%)
No 6/17 (36%) 46/133 (34%)
Abdominal pain 7/16 (44%) 33/127 (26%)
Antibiotics
In prior 3 months 16/17 (94%)b 84/131 (64%)b
No 1/17 (6%) 47/131 (36%)
Gastric tube feeding 3/17 (18%) 27/133 (20%)
Chemotherapy 2/17 (12%) 21/133 (16%)
Prior CDI 2/17 (12%) 5/133 (4%)
Proton pump inhibitor 8/17 (47%) 50/133 (38%)
Immunocompromised 7/17 (42%) 62/133 (47%)
Ward
Medical 8/17 (47%) 76/133 (57%)
Surgical 6/17 (35%) 25/133 (19%)
ICU 0/17 4/133 (3%)
Hematology/oncology 3/17 (18%) 28/133 (21%)
WBC
>15×109/l 6/17 (35%)b 14/133 (10%)b
<15×109/l 9/17 (53%) 110/133 (83%)
Unknown 2/17 (12%) 9/133 (7%)
CRP
<5 mg/l 3/17 (18%) 11/133 (8%)
>15 mg/l 10/17 (59%) 83/133 (62%)
5–15 mg/l 1/17 (6%) 17/133 (13%)
Unknown 3/17 (18%) 22/133 (17%)
CDI: Clostridium difficile infection; ICU: intensive care unit; WBC:
white blood cell count; CRP: C-reactive protein
a Including one patient with a positive PCR only
b p<0.05
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with positive results for C. difficile increased by more than
50%. From 1 January 2010 until 30 June 2010, before
implementation of the PCR, 895 stool specimens from 694
patients were tested and 7.3% of the specimens and 8.6%
(60) of the patients were positive for C. difficile using
ICTAB only. From 1 January 2011 until 30 June 2011, after
implementation of the PCR, 809 stool specimens from 657
patients were tested and 12.7% of the specimens and 13.5%
(89) of the patients were positive for C. difficile using the
PCR only. Two of the 103 PCR-positive specimens were not
available for culture. Of the remaining 101 specimens, all
were confirmed by culture except for one.
Discussion
PCR is a sensitive and specific method for the detection of
toxin-producing C. difficile. In this study, the sensitivity and
specificity were 100 and 99%, respectively, using TC as the
gold standard, which is in keeping with previous studies [1].
CTT was positive in only 70% of the specimens with a
positive TC and the EIAs used had a sensitivity of 47 and
58.8%. The specificity of CTT, ICTAB, and ELISA were
100, 99, and 89%, respectively. The low sensitivity of
ICTAB could not be ascribed to the presence of difficult-
to-detect ribotypes as described previously; only 2 of the 9
false-negative were type 002 [17].
The interpretation of a positive TC and/or PCR result is
difficult since asymptomatic carriage of C. difficile occurs
frequently. In our study, TC/PCR as well as CTT was
positive in only one of 141 healthy volunteers (0.7%). Other
studies have detected asymptomatic carriage of toxigenic C.
difficile in healthy subjects of between 0.5 and 13% [18, 19].
Moreover, in hospitalized patients, carriage has been described
in up to 14% [20, 21]. Therefore, the mere demonstration ofC.
difficile capable of producing toxin A and/or B does not
necessarily mean that it is the causative agent of the clinical
signs and symptoms in a patient [20].
Taking this relatively high occurrence of asymptomatic
carriage into consideration, one could hypothesize that the
demonstration of toxin activity directly in the stool by CTT
may be more predictive for the presence of CDI. However, the
CTT was also positive in the one healthy volunteer in this
study, and in a study by Kyne et al., 79% of 19 asymptomatic
carriers had a positive CTT directly in stool [20].
The median CT value was higher in the patients with a
negative CTT compared to the patients who were TC-, PCR-,
and CTT-positive. However, in this small series, there was
considerable overlap of CTs. It, therefore, does not seem to be
helpful to determine the clinical significance in the individual
patient.
In addition to the fact that laboratory tests cannot distin-
guish between infection and colonization, in many cases, a
clinical diagnosis of CDI is complicated because hospital-
ized patients with diarrhea due to C. difficile share signs and
symptoms with diarrhea due to other causes, especially
antibiotic treatment itself. Indeed, in the patients included
in this study, who were already identified to be at risk for
CDI by the clinician, there were no significant differences
between patients with and without a positive result for C.
difficile with respect to clinical presentation, except for more
prior antibiotic use and a higher WBC in patients with
positive results. Even in retrospect, a clinical diagnosis of
CDI was difficult to establish. Since the routine diagnosis of
C. difficile in our laboratory was based solely on the ICTAB
results and the other tests were done later in batch, we
identified nine additional patients with positive TC, of
whom five had a positive CTT and one patient with a
negative TC and positive PCR. Review of their medical
records showed that, in one patient with a positive CTT, a
diagnosis of CDI was established by endoscopy and another
patient with a positive CTTwas successfully treated for CDI
despite the negative routine results. On the other hand,
symptoms resolved within 2 days in two patients with a
positive CTT despite the continuation of antibiotics and one
patient had a diagnosis of GVHD. Thus, except in one
patient, CDI could not be proven, but it certainly could not
be ruled out either since CDI may be self-limiting. Even the
patient with an alternative diagnosis of GVHD may have
had concurrent CDI. In the five patients who were positive
by PCR and negative by CTT (one was also TC-negative), a
clinical diagnosis of CDI could also not be established in
retrospect: one was diagnosed with extensive GVHD and
the other four patients recovered without intervention.
Community-acquired CDI and CDI in the absence of a
history of antibiotic use are increasingly reported and
will further complicate a clinical diagnosis of CDI in the
future [22].
After substitution of ICTAB by the PCR in the routine
clinical laboratory, the percentage of positive patients
increased by more than 50%, which confirms the high sensi-
tivity of the PCR described in this study in a larger number of
patients with 809 specimens from 657 patients tested, of
which 103 specimens were positive. The specificity for the
presence of toxigenic C. difficile in the stool was also con-
firmed, as 100 of the 101 PCR-positive specimens were
confirmed by TC.
In conclusion, PCR for the detection of toxigenic C.
difficile has a high sensitivity and can rule out CDI, but
it cannot differentiate CDI from asymptomatic carriage.
CTT does not seem to differentiate between infection
and carriage either. Clinicians should be aware of the
occurrence of asymptomatic carriage to prevent inappro-
priate administration of antibiotics or cessation of anti-
biotic therapy, and to prevent delay of other diagnostics
or therapy.
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